Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions
2024年12月18日 - 10:30PM
ビジネスワイヤ(英語)
Tempus, a technology company leading the adoption of AI to
advance precision medicine and patient care, today announced that
the company has signed agreements for in-network provider status
with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of
California, and Avalon Healthcare Solutions, a laboratory benefit
manager. As part of the agreement with Avalon, Tempus is a
participating provider with BCBS North Carolina, BCBS South
Carolina, BCBS Vermont, Capital BlueCross and CareSource in four
markets. This enhances our work with commercial health plans in the
East.
Patients with these insurance plans will now have access to
Tempus testing as a participating provider. Tempus’ comprehensive
molecular profiling portfolio provides physicians and their
patients the solutions necessary to personalize treatment decisions
throughout their journey. Now, as an in-network laboratory, Tempus’
collection of assays can be applied to optimize patients’ care and
may lead to lower out-of-pocket costs for patients who receive any
such testing in accordance with their individual plan.
“Molecular profiling tests are increasingly a critical part of
patients’ treatment journeys as they enable physicians to make more
informed decisions on a deeply personalized level,” said Ezra
Cohen, MD, Chief Medical Officer of Oncology at Tempus. “In
addition to offering one of the most comprehensive testing
portfolios, our mission is to expand access to the many patients in
need of optimized care.”
To learn more about our testing portfolio, visit
tempus.com/oncology.
About Tempus
Tempus is a technology company advancing precision medicine
through the practical application of artificial intelligence in
healthcare. With one of the world’s largest libraries of multimodal
data, and an operating system to make that data accessible and
useful, Tempus provides AI-enabled precision medicine solutions to
physicians to deliver personalized patient care and in parallel
facilitates discovery, development and delivery of optimal
therapeutics. The goal is for each patient to benefit from the
treatment of others who came before by providing physicians with
tools that learn as the company gathers more data. For more
information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended (the “Securities Act”), and Section 21E of the Securities
Exchange Act of 1934, as amended, about Tempus and Tempus’ industry
that involve substantial risks and uncertainties. All statements
other than statements of historical facts contained in this press
release are forward-looking statements, including, but not limited
to, statements regarding the expected benefits of Tempus’ test
offerings and its capabilities for physicians. In some cases, you
can identify forward-looking statements because they contain words
such as “anticipate,” “believe,” “contemplate,” “continue,”
“could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,” or
“would” or the negative of these words or other similar terms or
expressions. Tempus cautions you that the foregoing may not include
all of the forward-looking statements made in this press
release.
You should not rely on forward-looking statements as predictions
of future events. Tempus has based the forward-looking statements
contained in this press release primarily on its current
expectations and projections about future events and trends that it
believes may affect Tempus’ business, financial condition, results
of operations and prospects. These forward-looking statements are
subject to risks and uncertainties related to: Tempus’ financial
performance; the ability to attract and retain customers and
partners; managing Tempus’ growth and future expenses; competition
and new market entrants; compliance with new laws, regulations and
executive actions, including any evolving regulations in the
artificial intelligence space; the ability to maintain, protect and
enhance Tempus’ intellectual property; the ability to attract and
retain qualified team members and key personnel; the ability to
repay or refinance outstanding debt, or to access additional
financing; future acquisitions, divestitures or investments; the
potential adverse impact of climate change, natural disasters,
health epidemics, macroeconomic conditions, and war or other armed
conflict, as well as risks, uncertainties, and other factors
described in the section titled “Risk Factors” in Tempus’ Quarterly
Report on Form 10-Q for the quarter ended September 30, 2024 filed
with the Securities and Exchange Commission (“SEC”) as well as in
other filings Tempus may make with the SEC in the future. In
addition, any forward-looking statements contained in this press
release are based on assumptions that Tempus believes to be
reasonable as of this date. Tempus undertakes no obligation to
update any forward-looking statements to reflect events or
circumstances after the date of this press release or to reflect
new information or the occurrence of unanticipated events, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241218016984/en/
Erin Caron media@tempus.com 773-612-4414
Tempus AI (NASDAQ:TEM)
過去 株価チャート
から 11 2024 まで 12 2024
Tempus AI (NASDAQ:TEM)
過去 株価チャート
から 12 2023 まで 12 2024